As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, autoimmune diseases, and many other conditions. With the market for these therapies forecast to double by 2030, it might seem that the only thing they can’t do is grow fast enough. New research from the University of Oklahoma aims to put an end to that limitation, too.
This article was originally published on MedicalXpress.com

